<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089359</url>
  </required_header>
  <id_info>
    <org_study_id>PRIUS</org_study_id>
    <nct_id>NCT03089359</nct_id>
  </id_info>
  <brief_title>Prehospital Recognition and Identification of Unspecific Symptoms</brief_title>
  <acronym>PRIUS</acronym>
  <official_title>Prehospital Recognition and Identification of Unspecific Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the predictive value of soluvent urokinase plasminogen activator&#xD;
      receptor (suPAR) and lactate with respect to serious conditions among patients presenting to&#xD;
      the EMS with unspecific symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2015</start_date>
  <completion_date type="Actual">March 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serious condition</measure>
    <time_frame>During medical care event</time_frame>
    <description>Predefined serious condition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24hours and 30 days</time_frame>
    <description>24h and 30 day mortality</description>
  </secondary_outcome>
  <enrollment type="Actual">414</enrollment>
  <condition>Serious Condition</condition>
  <condition>Morality</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Unspecific symptoms presenting to the EMS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unspecific symptoms (not feeling well, decreased general health condition, unable to&#xD;
             cope with usual daily activities, feeling weak)&#xD;
&#xD;
          -  Normal vital signs&#xD;
&#xD;
          -  Transported to ED&#xD;
&#xD;
          -  Able to give informed consent/ Next of kin gives informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Specific symptoms&#xD;
&#xD;
          -  under 18 years of age&#xD;
&#xD;
          -  Stays home / other caregiver than ED&#xD;
&#xD;
          -  Referral from caregiver&#xD;
&#xD;
          -  No personal numer (social security number)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Katarina Bohm, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Katarina Bohm</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Unspecific symptoms</keyword>
  <keyword>Soluvent urokinase plasminogen activator receptor</keyword>
  <keyword>Lactate</keyword>
  <keyword>Emergency Medical Services</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

